Register Login

Bleeding Disorders

Oct 25 2025
george

Precision BioLogic Webinar: Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay

Listen as Precision BioLogic’s Chief Scientific Officer F. Jon Geske, PhD and Marketing Director Ian Burns chair the webinar, Advancing Hemophilia A Testing with a Bovine Chromogenic FVIII Assay. Joining them are… Tara Quinton, R&D Scientist and part of Precision BioLogic’s Chromogenic FVIII assay design team, discussing the assay’s expanded utility along with new data […]
read more
Comments (0)
Bleeding Disorders
Oct 21 2025
george

Activated Protein Complex Concentrate in Emicizumab Prophylaxis

Here is a current open-access review describing APCC usage in emicizumab therapy: Sidonio RF Jr, Young G, Escuriola Ettingshausen C, et al. Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice. Res Pract Thromb Haemost. 2025;9:102926. doi: 10.1016/j.rpth.2025.102926. PMID: 40808796; PMCID: PMC12346059. Abstract Nonfactor therapies (NFTs) such as emicizumab are increasingly […]
read more
Comments (0)
Bleeding Disorders
Sep 25 2025
george

Incubation to Inactivate Efanesoctocog Alfa Prior to Inhibitor Bethesda Titer

Click here for an open-access letter that indicates the need to inactivate plasma EHL FVIII efanesoctocog alfa (Altuuviiio®; Altuvoct®) before performing a Bethesda titer to measure anti-FVIII inhibitor: Bowyer A. Is incubation for 30 minutes at 56°C sufficient to fully inactivate efanesoctocog alfa? Haemophilia. 2025. doi: 10.1111/hae.70137. PMID: 40985057. The findings provide a recommended incubation […]
read more
Comments (0)
Bleeding Disorders
Sep 17 2025
george

A Review of Current and Developing DOAC Reversal Agents

Check with your medical library for this comprehensive review of current and developing DOAC reversal agents:  Gómez-Outes A, Suárez-Gea ML, Lecumberri R. When and how to use reversal agents for direct oral anticoagulants? Curr Cardiol Rep. 2023;25:371–80. doi: 10.1007/s11886-023-01858-x. PMID: 36976497. Abstract Purpose of review: Our objective is to describe currently available reversal agents for […]
read more
Comments (0)
Anticoagulant Therapy
Sep 10 2025
george

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]
read more
Comments (0)
Bleeding Disorders
Aug 30 2025
george

NXT007: A First-in-human Study of a Factor Bypassing Hemophilia Therapy

Check with your medical library for a copy of  Sambe T, Miwa T, Yoneyama K, et al. A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. J Thromb Haemost. 2025: S1538–7836(25)00399-X. doi: 10.1016/j.jtha.2025.06.013. PMID: 40554054. Here’s the abstract: Background: NXT007 is a bispecific antibody that mimics the cofactor function […]
read more
Comments (0)
Bleeding Disorders
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

Which is an antifibrinolytic used to control bleeding?